Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Liquidia Has Filed Litigation In The U.S. District Court Of The District Of Columbia That Challenges The Recent FDA Decision To Grant 3-year New Clinical Investigation Exclusivity (NCI Exclusivity) To Tyvaso DPI

Author: Benzinga Newsdesk | August 22, 2024 06:05am

FDA granted tentative approval of YUTREPIA (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) patients on August 16, 2024. As a result of the FDA's award of NCI exclusivity to Tyvaso DPI, the final approval of YUTREPIA (treprostinil) inhalation powder is currently delayed until after the expiration of the exclusivity on May 23, 2025.

Posted In: LQDA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist